Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
How a small pet food manufacturer supports a 5x increase in production capacity
For Advanced Pet Care of Australia, scaling into one of Australia’s top pet food manufacturers required more than new production capacity – it required better systems.
